期刊文献+

ZSP0678的合成工艺研究

Study on the synthetic process of ZSP0678
原文传递
导出
摘要 目的优化PPARα/δ双重激动剂ZSP0678的合成工艺。方法以(E)-2-{2,6-二甲基-4-[4-(4-甲硫基苯基)-4-氧代-2-丁烯-1-基]苯氧基}-2-甲基丙酸乙酯(2)为起始原料,经环化、水解、手性拆分、酰胺化反应得到ZSP0678。结果目标化合物的结构经1H-NMR、13C-NMR和ESI-MS谱确证,总收率为6.5%(以化合物2计),化学纯度为98.6%(HPLC),光学纯度为99.2%。结论该工艺操作简便,避免使用柱色谱分离提纯,提高了总收率,有利于ZSP0678的大量制备。 ZSP0678 is a PPARα/δdual agonists.Herein,the synthetic process of ZSP0678 was studied.The ZSP0678 was synthesized via cyclization,hydrolysis,chiral separation and amidation reaction using ethyl(E)-2-(2,6-dimethyl-4-(4-(4-(methylthio)phenyl)-4-oxobut-2-en-1-yl)phenoxy)-2-methylpropanoate as the starting material.The structures of ZSP0678 was identified by~1H-NMR,13C-NMR and ESI-MS.The purity of the target compound was 98.6%(HPLC),and the chiral purity was 99.2%.The improved process has several advantages,such as simple operation,easy separation and purification and higher yield,and was suitable for large scale preparation.
作者 刘呈武 周光强 李波 蔡泽绵 LIU Cheng-wu;ZHOU Guang-qiang;LI Bo;CAI Ze-mian(Technology Development Department,G uangdong Zhongsheng Raynovent Biotechnology Co.,Ltd.,G uangzhou 510700,China)
出处 《中国药物化学杂志》 CAS CSCD 2022年第12期926-930,共5页 Chinese Journal of Medicinal Chemistry
关键词 ZSP0678 PPARα/δ双重激动剂 合成工艺 ZSP0678 PPARα/δdual agonists synthetic process
  • 相关文献

参考文献5

二级参考文献83

  • 1何晓瑜,成军.线粒体在非酒精性脂肪肝的作用[J].中国肝脏病杂志(电子版),2010,2(4):60-62. 被引量:5
  • 2Zhe-feng CAI Quan LIU Ping-ping LI Zong-ru GUO Zhu-fang SHEN.Synthesis and anti-diabetic activity of(RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid[J].Acta Pharmacologica Sinica,2006,27(5):597-602. 被引量:2
  • 3[1]Juge-Aubry C,Pemin A,Favez T,et al.DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements.Importance of the 5'-flanking region[J].J Biol Chem,1997,272:25252.
  • 4[2]Willson TM,Brown PJ,Sternbach DD,et al.The PPARs:from orphan receptors to drug discovery[J].J Med Chem,2000,43(4):527.
  • 5[3]Desvergne B,Michalik L,Wahli W.Be fit or be sick:peroxisome proliferator-activated receptors are down the road[J].Mol Endocrinol,2004,18:1321.
  • 6[4]Argmann CA,Cock TA,Auwerx J.Peroxisome proliferator-activated receptor gamma:the more the merrier?[J].Eur J Clin Invest,2005,35:82.
  • 7[5]Nagy L,Tontonoz P,Alvarez JG,et al.Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma[J].Cell,1998,93(2):229.
  • 8[6]Fruchart JG,Staels B,Duriez P.The role of fibric acids in atherosclerosis[J].Curr Atheroscler Rep,2001,3:83.
  • 9[7]Staels B,Fruchart JC.Therapeutic roles of peroxisome proliferatoractivated receptor agonists[J].Diabetes,2005,54:2460.
  • 10[8]Giannini S,Serio M,Galli A.Pleiotropic effects of thiazolidinediones:taking a look beyond antidiabetic activity[J]J Endocrinol Invest,2004,27:982.

共引文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部